NNC9204-0530

DRUG3 trials

Sponsors

Novo Nordisk A/S

Conditions

Metabolism and Nutrition DisorderObesity

Phase 1

Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

CompletedNCT02235961

Novo Nordisk A/SMetabolism and Nutrition Disorder, Obesity

Start: 2014-09-04End: 2016-07-06Updated: 2017-07-27

A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity

CompletedNCT02835235

Novo Nordisk A/SMetabolism and Nutrition Disorder, Obesity

Start: 2016-07-26End: 2017-07-07Updated: 2018-01-08

Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity

CompletedNCT02870231

Novo Nordisk A/SMetabolism and Nutrition Disorder, Obesity

Start: 2016-08-18End: 2017-09-03Updated: 2018-09-05